Initial testing (stage 1) of SGI-1776, a PIM1 kinase inhibitor, by the pediatric preclinical testing program

Pediatric Blood and Cancer

Volumn 59, Issue 4, 2012, Pages 749-752

  Batra, Vandana ^a   Maris, John M ^a,b   Kang, Min H ^c   Reynolds, C Patrick ^c   Houghton, Peter J ^d   Alexander, Denise ^d   Kolb, E Anders ^e   Gorlick, Richard ^f   Keir, Stephen T ^g   Carol, Hernan ^h   Lock, Richard ^h   Billups, Catherine A ⁱ   Smith, Malcolm A ^j  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^d NATIONWIDE CHILDREN S HOSPITAL   (United States)

^e NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

^f CHILDREN S HOSPITAL AT MONTEFIORE   (United States)

^g DUKE UNIVERSITY MEDICAL CENTER   (United States)

^h CHILDREN S CANCER INSTITUTE AUSTRALIA FOR MEDICAL RESEARCH   (Australia)

ⁱ ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^j NATIONAL CANCER INSTITUTE   (United States)

more..

Author keywords

Developmental therapeutics; Kinase inhibitors; Preclinical testing

Indexed keywords

PHOSPHOTRANSFERASE INHIBITOR; PROTEIN KINASE PIM 1; SGI 1776; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CHILDHOOD CANCER; CONTROLLED STUDY; CYTOTOXICITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG SCREENING; EWING SARCOMA; GLIOBLASTOMA; HUMAN; HUMAN CELL; IC 50; MAXIMUM TOLERATED DOSE; MEDULLOBLASTOMA; MOUSE; NEPHROBLASTOMA; NEUROBLASTOMA; NONHUMAN; OSTEOSARCOMA; PEDIATRIC PRECLINICAL TESTING PROGRAM; PRIORITY JOURNAL; RHABDOID TUMOR; SOLID TUMOR; TUMOR XENOGRAFT;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SCREENING ASSAYS, ANTITUMOR; IMIDAZOLES; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASMS; PHOSPHOPROTEINS; PROTO-ONCOGENE PROTEINS C-PIM-1; PYRIDAZINES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84864928386     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.23364     Document Type: Article

References (20)

1. Reeves R, Spies GA, Kiefer M, et al. Primary structure of the putative human oncogene, pim-1. Gene 1990; 90: 303-307.
2. Shah N, Pang B, Yeoh KG, et al. Potential roles for the PIM1 kinase in human cancer-A molecular and therapeutic appraisal. Eur J Cancer 2008; 44: 2144-2151.
3. Saris CJ, Domen J, Berns A. The pim-1 oncogene encodes two related protein-serine/threonine kinases by alternative initiation at AUG and CUG. EMBO J 1991; 10: 655-664.
4. Cuypers HT, Selten G, Quint W, et al. Murine leukemia virus-induced T-cell lymphomagenesis: Integration of proviruses in a distinct chromosomal region. Cell 1984; 37: 141-150.
5. Moroy T, Verbeek S, Ma A, et al. E mu N- and E mu L-myc cooperate with E mu pim-1 to generate lymphoid tumors at high frequency in double-transgenic mice. Oncogene 1991; 6: 1941-1948.
6. van Lohuizen M, Verbeek S, Krimpenfort P, et al. Predisposition to lymphomagenesis in pim-1 transgenic mice: Cooperation with c-myc and N-myc in murine leukemia virus-induced tumors. Cell 1989; 56: 673-682.
7. Macdonald A, Campbell DG, Toth R, et al. Pim kinases phosphorylate multiple sites on Bad and promote 14-3-3 binding and dissociation from Bcl-XL. BMC Cell Biol 2006; 7: 1.
8. Grundler R, Brault L, Gasser C, et al. Dissection of PIM serine/threonine kinases in FLT3-ITD-induced leukemogenesis reveals PIM1 as regulator of CXCL12-CXCR4-mediated homing and migration. J Exp Med 2009; 206: 1957-1970.
9. Roh M, Gary B, Song C, et al. Overexpression of the oncogenic kinase Pim-1 leads to genomic instability. Cancer Res 2003; 63: 8079-8084.
10. Zippo A, De Robertis A, Bardelli M, et al. Identification of Flk-1 target genes in vasculogenesis: Pim-1 is required for endothelial and mural cell differentiation in vitro. Blood 2004; 103: 4536-4544.
11. Bachmann M, Hennemann H, Xing PX, et al. The oncogenic serine/threonine kinase Pim-1 phosphorylates and inhibits the activity of Cdc25C-associated kinase 1 (C-TAK1): A novel role for Pim-1 at the G2/M cell cycle checkpoint. J Biol Chem 2004; 279: 48319-48328.
12. Mochizuki T, Kitanaka C, Noguchi K, et al. Physical and functional interactions between Pim-1 kinase and Cdc25A phosphatase. Implications for the Pim-1-mediated activation of the c-Myc signaling pathway. J Biol Chem 1999; 274: 18659-18666.
13. Wang Z, Bhattacharya N, Mixter PF, et al. Phosphorylation of the cell cycle inhibitor p21Cip1/WAF1 by Pim-1 kinase. Biochim Biophys Acta 2002; 1593: 45-55.
14. Amson R, Sigaux F, Przedborski S, et al. The human protooncogene product p33pim is expressed during fetal hematopoiesis and in diverse leukemias. Proc Natl Acad Sci USA 1989; 86: 8857-8861.
15. Kumar A, Mandiyan V, Suzuki Y, et al. Crystal structures of proto-oncogene kinase Pim1: A target of aberrant somatic hypermutations in diffuse large cell lymphoma. J Mol Biol 2005; 348: 183-193.
16. Chen LS, Redkar S, Bearss D, et al. Pim kinase inhibitor, SGI-1776 induces apoptosis in chronic lymphocytic leukemia cells. Blood 2009; 114: 4150-4157.
17. Frgala T, Kalous O, Proffitt RT, et al. A fluorescence microplate cytotoxicity assay with a 4-log dynamic range that identifies synergistic drug combinations. Mol Cancer Ther 2007; 6: 886-897.
18. Houghton PJ, Morton CL, Tucker C, et al. The pediatric preclinical testing program: Description of models and early testing results. Pediatr Blood Cancer 2007; 49: 928-940.
19. Keir ST, Morton CL, Billups C, et al. Initial testing of VNP40101M (Cloretazine) by the pediatric preclinical testing program. Pediatr Blood Cancer 2008; 51: 439-441.
20. Liem NL, Papa RA, Milross CG, et al. Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies. Blood 2004; 103: 3905-3914.